B
CSTL icon

Braidwell’s Castle Biosciences CSTL Stock Holding History

Braidwell’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-177,183
Closed -$6.89M – 92
2025
Q4 		$6.89M Sell
177,183
-645,552
-78% -$20.8M 0.22% 68
2025
Q3 		$18.7M Hold
822,735
– – 0.56% 47
2025
Q2 		$16.8M Buy
822,735
+457,488
+125% +$8.47M 0.57% 44
2025
Q1 		$7.31M Buy
+365,247
New +$9.04M 0.26% 54
2024
Q4 		– Sell
-331,986
Closed -$9.47M – 78
2024
Q3 		$9.47M Sell
331,986
-84,114
-20% -$2.14M 0.27% 66
2024
Q2 		$9.06M Buy
+416,100
New +$9.27M 0.28% 61

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Braidwell's CSTL Position: Q1 2026 in Review

Braidwell sold out of Castle Biosciences (CSTL) in Q1 2026, closing a stake of 177,183 shares — an estimated $6.89M sold.

Braidwell first reported a position in CSTL in Q2 2024 and held it in 6 quarters. The position peaked at $18.7M in Q3 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Braidwell reported no remaining Castle Biosciences position as of Q1 2026 after selling out during the quarter.
  • Braidwell sold 177,183 Castle Biosciences shares in Q1 2026, an estimated $6.89M.
  • Braidwell first reported a position in Castle Biosciences in Q2 2024 and held it in 6 quarters.
  • Braidwell's Castle Biosciences position peaked at $18.7M in Q3 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Braidwell's 13F filing for Q1 2026, filed 15 May 2026.